BlackRock
KROS icon

BlackRock’s Keros Therapeutics KROS Stock Holding History

BlackRock’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.9M Buy
2,794,217
+382,424
+16% +$4.26M ﹤0.01% 3001
2026
Q1 		$26.6M Buy
2,411,793
+121,261
+5% +$1.87M ﹤0.01% 2901
2025
Q4 		$46.6M Sell
2,290,532
-426,621
-16% -$7.48M ﹤0.01% 2562
2025
Q3 		$43M Sell
2,717,153
-15,470
-0.6% -$229K ﹤0.01% 2600
2025
Q2 		$36.5M Sell
2,732,623
-52,614
-2% -$710K ﹤0.01% 2633
2025
Q1 		$28.4M Buy
2,785,237
+55,959
+2% +$650K ﹤0.01% 2732
2024
Q4 		$43.2M Buy
2,729,278
+96,670
+4% +$5.02M ﹤0.01% 2546
2024
Q3 		$153M Buy
2,632,608
+119,364
+5% +$5.9M ﹤0.01% 1816
2024
Q2 		$115M Buy
2,513,244
+347,234
+16% +$18.7M ﹤0.01% 1945
2024
Q1 		$143M Buy
2,166,010
+129,222
+6% +$7.66M ﹤0.01% 1850
2023
Q4 		$81M Buy
2,036,788
+169,439
+9% +$5.31M ﹤0.01% 2206
2023
Q3 		$59.5M Buy
1,867,349
+122,952
+7% +$4.59M ﹤0.01% 2305
2023
Q2 		$70.1M Buy
1,744,397
+67,137
+4% +$2.94M ﹤0.01% 2282
2023
Q1 		$71.6M Buy
1,677,260
+38,934
+2% +$1.97M ﹤0.01% 2223
2022
Q4 		$78.7M Buy
1,638,326
+177,136
+12% +$8.27M ﹤0.01% 2173
2022
Q3 		$55M Buy
1,461,190
+64,847
+5% +$2.25M ﹤0.01% 2370
2022
Q2 		$38.6M Buy
1,396,343
+98,297
+8% +$4.31M ﹤0.01% 2664
2022
Q1 		$70.6M Buy
1,298,046
+11,520
+0.9% +$591K ﹤0.01% 2361
2021
Q4 		$75.3M Buy
1,286,526
+52,368
+4% +$2.61M ﹤0.01% 2390
2021
Q3 		$48.8M Sell
1,234,158
-5,215
-0.4% -$186K ﹤0.01% 2673
2021
Q2 		$52.6M Buy
1,239,373
+15,328
+1% +$830K ﹤0.01% 2667
2021
Q1 		$75.3M Buy
1,224,045
+24,844
+2% +$1.57M ﹤0.01% 2358
2020
Q4 		$84.6M Buy
1,199,201
+544,559
+83% +$34.3M ﹤0.01% 2171
2020
Q3 		$25.2M Sell
654,642
-5,679
-0.9% -$225K ﹤0.01% 2731
2020
Q2 		$24.8M Buy
+660,321
New +$20.3M ﹤0.01% 2685

Other funds holding KROS

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

BlackRock's KROS Position: Q2 2026 in Review

BlackRock increased its Keros Therapeutics (KROS) stake by 16% in Q2 2026, buying an estimated $4.26M and bringing the position to 2,794,217 shares worth $29.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3001.

BlackRock first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $153M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • BlackRock held 2,794,217 shares of Keros Therapeutics worth $29.9M as of Q2 2026.
  • BlackRock bought 382,424 Keros Therapeutics shares in Q2 2026, an estimated $4.26M.
  • Keros Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3001 holding.
  • BlackRock first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • BlackRock's Keros Therapeutics position peaked at $153M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.